Anxiety and depression are two of the most prevalent mental health disorders worldwide, affecting millions of individuals across all demographics. Anxiety is characterized by persistent feelings of worry, fear, and apprehension, often accompanied by physical symptoms such as increased heart rate, sweating, and trembling. It can appear in diverse manifestations such as generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobias. Depression, on the other hand, is marked by persistent feelings of sadness, hopelessness, and disinterest in activities once enjoyed. It may also manifest in physical symptoms such as alterations in appetite and sleep routines, fatigue, and challenges with focus. Major depressive disorder and persistent depressive disorder are common forms of depression, both of which significantly impact daily functioning and quality of life. These disorders often coexist, with individuals experiencing symptoms of both anxiety and depression simultaneously, known as comorbid anxiety-depression. The causes of these conditions are multifaceted, involving a combination of genetic, environmental, and psychological factors. Traumatic life events, chronic stress, imbalances in brain chemistry, and genetic predispositions can all contribute to the development of anxiety and depression. Treatment typically involves a combination of therapy, medication, and lifestyle changes. Cognitive-behavioral therapy (CBT) and other forms of psychotherapy can help individuals understand and manage their thoughts and behaviors, while medications such as antidepressants and anti-anxiety medications can alleviate symptoms. Additionally, lifestyle modifications such as regular exercise, healthy diet, adequate sleep, and stress management techniques are essential components of a comprehensive treatment plan. Early intervention and ongoing support are crucial for effectively managing anxiety and depression and improving overall well-being.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom